Atlantic Lipid Lowering Treatment Optimization Program

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-120
SponsorAtlantic Health System

About this trial

Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level. We aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level. Our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients' primary care providers to provide comprehensive medical management.

Eligibility criteria

Qualifiers

LDL-C ≥160 mg/dL

Untreated LDL-C ≥190 with family history of CAD

Prior MI and currently without optimized lipid-lowering therapy

Family history of CAD in first degree relative

Disqualifiers

Individuals who are pregnant

Individuals who are incarcerated

Individuals with a terminal illness

Individuals who do not consent

Trial design

Treatments tested in this trial

  • Supportive care

Treatment groups

250 Participants
are divided into 1 treatment group

Sponsors and collaborators

Atlantic Health System

Lead sponsor

Regeneron Pharmaceuticals

Collaborator